Overview

Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy and safety of HL-040XC in patients with essential hypertension and hyperlipidemia
Phase:
Phase 3
Details
Lead Sponsor:
HanAll BioPharma Co., Ltd.
Treatments:
Atorvastatin
Atorvastatin Calcium
Losartan